Characteristics | Total(N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
Age | 367 | Â | Â | Â | Â |
 <  = 65 | 163 | Reference |  |  |  |
 > 65 | 204 | 1.620 (1.154–2.276) | 0.005 | 1.571 (1.029–2.398) | 0.036 |
Pathologic stage | 347 | Â | Â | Â | Â |
Stage I | 50 | Reference | Â | Â | Â |
Stage II&Stage III&Stage IV | 297 | 2.247 (1.210–4.175) | 0.010 | 1.004 (0.357–2.826) | 0.994 |
T stage | 362 | Â | Â | Â | Â |
T1 | 18 | Reference | Â | Â | Â |
T2&T3&T4 | 344 | 8.829 (1.234–63.151) | 0.030 | 1,533,097.7526 (0.000-Inf) | 0.995 |
N stage | 352 | Â | Â | Â | Â |
N0 | 107 | Reference | Â | Â | Â |
N1&N2&N3 | 245 | 1.925 (1.264–2.931) | 0.002 | 2.023 (1.022—4.004) | 0.043 |
M stage | 352 | Â | Â | Â | Â |
M0 | 327 | Reference | Â | Â | Â |
M1 | 25 | 2.254 (1.295–3.924) | 0.004 | 1.300 (0.575–2.943) | 0.528 |
Histologic grade | 361 | Â | Â | Â | Â |
G1 | 10 | Reference | Â | Â | Â |
G2&G3 | 351 | 1.957 (0.484–7.910) | 0.346 |  |  |
Primary therapy outcome | 313 | Â | Â | Â | Â |
CR | 229 | Reference | Â | Â | Â |
PD&SD&PR | 84 | 4.228 (2.905–6.152) |  < 0.001 | 4.130 (2.624–6.500) |  < 0.001 |
Helicobacter pylori infection | 162 | Â | Â | Â | Â |
No | 144 | Reference | Â | Â | Â |
Yes | 18 | 0.650 (0.279–1.513) | 0.317 |  |  |
Residual tumor | 325 | Â | Â | Â | Â |
R0 | 294 | Reference | Â | Â | Â |
R1&R2 | 31 | 3.445 (2.160–5.494) |  < 0.001 | 1.169 (0.613–2.228) | 0.636 |
ITGB1 | 370 | Â | Â | Â | Â |
Low | 184 | Reference | Â | Â | Â |
High | 186 | 1.404 (1.008–1.956) | 0.045 | 1.103 (0.695–1.751) | 0.676 |
LUM | 370 | Â | Â | Â | Â |
Low | 185 | Reference | Â | Â | Â |
High | 185 | 1.433 (1.028–1.997) | 0.034 | 1.830 (1.045–3.203) | 0.034 |
COL5A2 | 370 | Â | Â | Â | Â |
Low | 186 | Reference | Â | Â | Â |
High | 184 | 1.496 (1.073–2.084) | 0.017 | 0.974 (0.571–1.662) | 0.923 |